Stay updated with breaking news from Johny humaloja. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ziccum AB has appointed Johny Humaloja as its new CFO. Johny is a financial executive with decades of experience in the biopharma and biotech industries in Europe and the US. He will assume his new. | June 2, 2023 ....
Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem into clinic LUND, Sweden, July 12, 2021 /PRNewswire/ Amniotics AB (publ) ( Amniotics or the Company ), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market. The offering was fully subscribed and attracted widespread interest from Swedish investment companies and family offices as well as the general public in Sweden, Norway and Finland. The funds will now be deployed to advance the company s preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022. In addition, Amniotics will expand its stem cell GMP manufacturing services to research and industry. ....
Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic USA - English News provided by Share this article LUND, Sweden, July 12, 2021 /PRNewswire/ Amniotics AB (publ) ( Amniotics or the Company ), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market. The offering was fully subscribed and attracted widespread interest from Swedish investment companies and family offices as well as the general public in Sweden, Norway and Finland. The funds will now be deployed to advance the company s preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022. In addition, Amniotics will expand its stem cell GMP manufacturing services ....